Home ProductsMedical Raw Materials

58186-27-9 Idebenone Skin Care Antioxidants , IDBN For Improving Mental Symptoms C19H30O5

Good quality Pharma Raw Material for sales
Good quality Pharma Raw Material for sales
I'm Online Chat Now

58186-27-9 Idebenone Skin Care Antioxidants , IDBN For Improving Mental Symptoms C19H30O5

China 58186-27-9 Idebenone Skin Care Antioxidants , IDBN For Improving Mental Symptoms C19H30O5 supplier

Large Image :  58186-27-9 Idebenone Skin Care Antioxidants , IDBN For Improving Mental Symptoms C19H30O5

Product Details:

Place of Origin: China
Brand Name: PooChun
Certification: ISO9001 SGS GMP DCGI DMF
Model Number: 58186-27-9

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 1~10 kg / Al-Pt bag,10kg / 25kg fiber drum
Delivery Time: 1-3days after payment
Payment Terms: T/T, L/C
Supply Ability: 1000kg per Month
Contact Now
Detailed Product Description
Name: Idebenone, IDBN CAS: 58186-27-9
MF: C19H30O5 MW: 338.439
Appearance: Orange Yellow Crystalline Powder Grade: Medicine Grade, Cosmetic Grade
Type: Anti Senile Dementia Manufacturer: GMP Factory
High Light:

steroid hormones


pharmaceutical raw materials

Idebenone Medicine Raw Material IDBN as External Antioxidants Improve Mental Symptoms C19H30O5





Idebenone ( pronounced eye - deb - eh - known, trade names Catena, Raxone, Sovrima, among others ) is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects.


The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed.


Chemically, idebenone is an organic compound of the quinone family. It is also promoted commercially as a synthetic analog of coenzyme Q10 (CoQ10).





Test Items Specifications Result
Aspect An orange yellow or yellow, crystalline powder. Orange yellow crystalline powder
Solubility Insoluble in water, very soluble in methanol, chloroform, freely soluble in anhydrous alcohol and ethyl acetate.
Identification 1. Comply with the standard
2. Comply with the standard
3. IR spectrum
E 458--486
Melting Range 52—55℃ 54-55℃
Loss on drying ≤0.1%


Residue on Ignition ≤0.1%


Heavy metals ≤10ppm Conforms
Impurities ≤0.8% 0.5%
Residue Solvents Hexane ≤0.029% Conforms
Methanol ≤0.3% Conforms
Toluene ≤0.089% Conforms
Assay(HPLC): ≥98.5%, anhydrous substance 99.7%

Packaging and storage:  Keep in a well - closed container.




Indications that are or were approved in some territories

Nootropic effects and Alzheimer's disease

Idebenone improved learning and memory in experiments with mice. In humans, evaluation of Surrogate endpoints like electroretinography, auditory evoked potentials and visual analogue scales also suggested positive nootropic effects, but larger studies with hard endpoints are missing.

Research on idebenone as a potential therapy of Alzheimer's disease have been inconsistent, but there may be a trend for a slight benefit. In May 1998, the approval for this indication was cancelled in Japan due to the lack of proven effects. In some European countries, the drug is available for the treatment of individual patients in special cases.

Friedreich's ataxia ( Sovrima )

Preliminary testing has been done in humans and found idebenone to be a safe treatment for Friedreich's ataxia ( FA ), exhibiting a positive effect on cardiac hypertrophy and neurological function. The latter was only significantly improved in young patients. In a different experiment, a one - year test on eight patients, idebenone reduced the rate of deterioration of cardiac function, but without halting the progression of ataxia.

The drug was approved for FA in Canada in 2008 under conditions including proof of efficacy in further clinical trials. However, on February 27, 2013, Health Canada announced that idebenone would be voluntarily recalled as of April 30, 2013 by its Canadian manufacturer, Santhera Pharmaceuticals, due to the failure of the drug to show efficacy in the further clinical trials that were conducted. In 2008, the European Medicines Agency ( EMA ) refused a marketing authorisation for this indication. As of 2013 the drug was not approved for FA in Europe nor in the US, where there is no approved treatment.

Indications being explored

Duchenne muscular dystrophy ( Catena )

After experiments in mice and preliminary studies in humans, idebenone has entered Phase II clinical trials in 2005 and Phase III trials in 2009.

Leber's hereditary optic neuropathy ( Raxone )

Leber's hereditary optic neuropathy ( LHON ) is a mitochondrially inherited ( mother to all offspring ) degeneration of retinal ganglion cells ( RGCs ) and their axons that leads to an acute or subacute loss of central vision; this affects predominantly young adult males. Santhera completed a Phase III clinical trial in this indication in Europe with positive results, and submitted an application to market the drug to European regulators in July 2011. In January 2013, the request for marketing authorisation was refused by the EMA.

Other neuromuscular diseases

Phase I and II clinical trials for the treatment of MELAS ( mitochondrial encephalomyopathy, lactic acidosis, and stroke - like episodes ) and primary progressive multiple sclerosis are ongoing as of December 2013.

Life style

Idebenone is claimed to have properties similar to CoQ10 in its antioxidant properties, and has therefore been used in anti - aging on the basis of free - radical theory. Clinical evidence for this use is missing. It has been used in topical applications to treat wrinkles.



Production Equipment


58186-27-9 Idebenone Skin Care Antioxidants , IDBN For Improving Mental Symptoms C19H30O5

Contact Details
Shanghai Poochun Industry Co.,Ltd

Send your inquiry directly to us (0 / 3000)